Sinekod syrup vanilla vials of dark glass, complete with a measuring cap, 1.5mg \ ml 200ml

Be the first to review this product

Special Price $27.72 Regular Price $28.00

In stock

SKU

FL102010235

554.4 Reward Points will be used to purchase this product

Category

Cough

Scope of the medicinal product

General

Release form

Syrup

Manufacturer country

Switzerland

Package quantity, pcs

one

Skip to the end of the images gallery

Skip to the beginning of the images gallery

Details

Description

Release form, composition and packaging

Syrup (vanilla) in the form of a colorless transparent liquid with a vanilla smell.

1 ml

butamirate citrate 1.5 mg

sorbitol solution 70% m / m - 40.5% m / v, glycerol - 29% m / v, sodium saccharinate - 0.06% m / v, benzoic acid - 1.115% m / v, vanillin - 0.06% m / vol., ethanol 96% vol./about.

- 0.25% m / v., Sodium hydroxide 30% m / m - 0.031% m / v., Water - up to 100 ml.

100 ml - dark glass bottles (1) complete with a measuring cap - cardboard packs.

200 ml - dark glass bottles (1) complete with a measuring cap - cardboard packs.

pharmachologic effect

Antitussive drug of central action, does not belong to opium alkaloids, either chemically or pharmacologically.

Does not form addiction or addiction.

Suppresses cough, having a direct effect on the cough center.

It has a bronchodilating effect.

Helps to facilitate breathing, improving spirometry (reduces airway resistance) and blood oxygenation.

Pharmacokinetics

Suction

Based on the available data, it is assumed that the butamirate ester is rapidly and completely absorbed and hydrolyzed in plasma, converting to 2-phenylbutyric acid and diethylaminoethoxyethanol.

The effect of food on absorption has not been studied.

The change in the concentration of 2-phenylbutyric acid and diethylaminoethoxyethanol occurs in proportion to the dose taken in the range of 22.5-90 mg.

Butamirate is rapidly and completely absorbed when taken orally, measured concentrations are found in the blood 5-10 minutes after ingestion in doses of 22.5 mg, 45 mg, 67.5 mg and 90 mg.

Cmax in blood plasma is achieved within 1 hour when taken in all 4 doses, the average is 16.1 ng / ml when taken orally at a dose of 90 mg.

Average plasma concentrations of 2-phenylbutyric acid are reached within 1.5 hours

Cmax was observed at a dose of 90 mg (3052 ng / ml)

average plasma concentrations of dithylaminoethoxyethanol are reached within 0.67 hours

Cmax is observed after taking at a dose of 90 mg (160 ng / ml).

Distribution

Butamirate has a large Vd in the range 81-112 L (corrected for body weight in kg), as well as a high degree of binding to plasma proteins.

2-phenylbutyric acid has a high degree of binding to plasma proteins at all doses (22.5-90 mg) and averages 89.3-91.6%.

Also, the ability of diethylaminoethoxyethanol to bind to plasma proteins is found, the average values вЂ�вЂ�vary within 28.8-45.7%.

It is not known whether butamirate crosses the placental barrier, whether it is excreted in breast milk.

Metabolism

Hydrolysis of butamirate, which results in the formation of 2-phenylbutyric acid and diethylaminoethoxyethanol, which have an antitussive effect, occurs very quickly.

2-phenylbutyric acid undergoes further partial metabolism by hydroxylation in the para-position.

Withdrawal

The excretion of three metabolites occurs mainly by the kidneys after conjugation in the liver, acidic metabolites bind largely to glucuronic acid. Conjugates of 2-phenylbutyric acid are detected in urine at significantly higher concentrations than in blood plasma. Butamirate is detected in urine within 48 hours, butamirate excreted in urine during the 96-hour sampling period accounts for about 0.02, 0.02, 0.03 and 0.03% of the doses taken 22.5 mg, 45 mg, 67.5 mg and 90 mg, respectively ... As a percentage, butamirate is excreted in the urine in greater amounts and in the form of diethylaminoethoxyethanol than unchanged butamirate or unconjugated 2-phenylbutyric acid. The measured T1 / 2 of 2-phenylbutyric acid, butamirate and diethylaminoethoxyethanol is 23.26-24.42, 1.48-1.93 and 2.72-2.90 h, respectively.

Indications for use

- symptomatic treatment of dry cough of various etiologies: suppression of cough in the pre- and postoperative period, during surgical interventions

Name ENG

SINECOD

Clinical and pharmacological group

Antitussive drug

ATX code

Butamirate

Dosage

1.5mg / ml x 200ml

Structure

Active ingredient: butamirate citrate - 0.150 (1.5 mg / ml).

Excipients: sorbitol solution 70% m / m 40.50, glycerol 29.00.

sodium saccharinate 0.06, benzoic acid 0.115, vanillin 0.06, ethanol 96% v / v.

0.25, sodium hydroxide 30% m / m 0.031, water up to 100 ml.

Indications

Symptomatic treatment of dry coughs of various etiologies:

cough in the preoperative and postoperative period

cough during surgery, bronchoscopy

with whooping cough.

INN / Active ingredient

Butamirat

Storage conditions and periods

At a temperature not higher than 30 degrees.

Expiration date: 3 years

Contraindications

hypersensitivity to drug components

children up to 2 months old (for drops)

children under 3 years old (for syrup)

I trimester of pregnancy

lactation period

intolerance to fructose (the drug contains sorbitol)

With care: II and III trimesters of pregnancy.

Due to the presence of ethyl alcohol in the composition of the drug, use with caution in patients with a tendency to develop drug dependence, with liver diseases, alcoholism, epilepsy, brain diseases, in pregnant women (II and III trimesters) and children.

Specifications

Submit your review to Earn 10 Reward Points click here to login

Write Your Own Review